Clinical trial of universal superbug antibody in Changzhou Fangyuan pharmaceutical company

Changzhou Fangyuan pharmaceutical company is preparing clinical trials to test the semi synthetic methicillin resistant antibodies and antibiotics against Gram-negative bacteria that it has spent nearly ten years to produce The drug, abecasin, is believed to be a key part of the resistance to the increasing resistance of bacteria China and other Asian countries, such as India, and even the world, will face serious problems in decades due to the overuse of antibiotics that make bacteria resistant According to the media, the new drug is expected to be put into production in 2018, and the universal drug, abecasin sulfuric acid, which is difficult to manufacture, will be used in the treatment of superbacteria At present, the drug has shown its great advantages The Chinese and Indian governments are trying to curb the abuse of antibiotics, hoping to solve the problem at the source With the help of advanced universities, government research institutions and foreign experts, Fangyuan pharmaceutical company has made progress in the research and development of innovative new aminoglycoside antibiotics, which can reduce the side effects of antibiotics on human body In addition, the company (located in Changzhou National High tech Zone) is also in the treatment of leukemia, colon cancer and other four non patent drugs The Chinese government is promoting the development of biotechnology in multi center cities of Shanghai, Suzhou and Changzhou through various policies and benefits At present, it has established about 2000 National incubators combining academic work and independent entrepreneurship.